• Something wrong with this record ?

Cost Burden of Severe Community-Acquired Rotavirus Gastroenteritis Requiring Hospitalization in the Czech Republic, Slovakia, Poland, and Hungary: A Retrospective Patient Chart Review

A. Tichopád, J. Müllerová, T. Jackowska, E. Nemes, P. Pazdiora, B. Sloesen, M. Štefkovičová,

. 2016 ; 10 (-) : 53-60. [pub] 20160910

Language English Country United States

Document type Journal Article

Persistent link   https://www.medvik.cz/link/bmc18034054

OBJECTIVES: To provide valuable local data on the economic burden of rotavirus gastroenteritis (RVGE) for decision making on introduction of rotavirus vaccination in Central European countries. METHODS: We conducted a retrospective patient hospital chart review during the winter RVGE peak in the Czech Republic (n = 109), Hungary (n = 109), Poland, (n = 112), and Slovakia (n = 115) to estimate resource use and associated costs from the payer's perspective in children younger than 5 years with severe RVGE requiring hospitalization. Microcosting analysis was used to estimate the average costs of treating RVGE inpatients including pre- and posthospitalization costs. RESULTS: The average cost of treatment was €476, €316, €741, and €594 in the Czech Republic, Hungary, Poland, and Slovakia, respectively. Extrapolating these costs to the total number of RVGE hospitalizations gives annual cost estimates of €2.1 million, €1.5 million, €13.2 million, and €1.5 million, respectively. The main component of expenditure in all the four countries is the hospital stay, but wide variation among countries was observed (total cost of treating RVGE in hospital was almost 2.5-fold higher in Poland than in Hungary). In countries with diagnosis related group (DRG) costs available, the best agreement between real resource-use-driven costs and the DRG cost was found in the Czech Republic and Hungary, with differences of only €22 and €33, respectively. In Poland, the microcosting indicated higher overall costs incurred in hospital than the DRG cost, with a difference exceeding €190. CONCLUSIONS: Hospitalization of children with RVGE represents a substantial economic burden for the national health systems in these countries.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc18034054
003      
CZ-PrNML
005      
20181203090706.0
007      
ta
008      
181008s2016 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.vhri.2016.07.005 $2 doi
035    __
$a (PubMed)27881278
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Tichopád, Aleš $u Kantar Health s.r.o., Prague, Czech Republic. Electronic address: ales.tichopad@kantarhealth.com.
245    10
$a Cost Burden of Severe Community-Acquired Rotavirus Gastroenteritis Requiring Hospitalization in the Czech Republic, Slovakia, Poland, and Hungary: A Retrospective Patient Chart Review / $c A. Tichopád, J. Müllerová, T. Jackowska, E. Nemes, P. Pazdiora, B. Sloesen, M. Štefkovičová,
520    9_
$a OBJECTIVES: To provide valuable local data on the economic burden of rotavirus gastroenteritis (RVGE) for decision making on introduction of rotavirus vaccination in Central European countries. METHODS: We conducted a retrospective patient hospital chart review during the winter RVGE peak in the Czech Republic (n = 109), Hungary (n = 109), Poland, (n = 112), and Slovakia (n = 115) to estimate resource use and associated costs from the payer's perspective in children younger than 5 years with severe RVGE requiring hospitalization. Microcosting analysis was used to estimate the average costs of treating RVGE inpatients including pre- and posthospitalization costs. RESULTS: The average cost of treatment was €476, €316, €741, and €594 in the Czech Republic, Hungary, Poland, and Slovakia, respectively. Extrapolating these costs to the total number of RVGE hospitalizations gives annual cost estimates of €2.1 million, €1.5 million, €13.2 million, and €1.5 million, respectively. The main component of expenditure in all the four countries is the hospital stay, but wide variation among countries was observed (total cost of treating RVGE in hospital was almost 2.5-fold higher in Poland than in Hungary). In countries with diagnosis related group (DRG) costs available, the best agreement between real resource-use-driven costs and the DRG cost was found in the Czech Republic and Hungary, with differences of only €22 and €33, respectively. In Poland, the microcosting indicated higher overall costs incurred in hospital than the DRG cost, with a difference exceeding €190. CONCLUSIONS: Hospitalization of children with RVGE represents a substantial economic burden for the national health systems in these countries.
650    12
$a osobní újma zaviněná nemocí $7 D017281
650    _2
$a Česká republika $7 D018153
650    _2
$a Evropa $7 D005060
650    _2
$a gastroenteritida $x ekonomika $x terapie $7 D005759
650    12
$a náklady na zdravotní péči $7 D017048
650    12
$a hospitalizace $7 D006760
650    _2
$a lidé $7 D006801
650    _2
$a Maďarsko $7 D006814
650    _2
$a Polsko $7 D011044
650    _2
$a retrospektivní studie $7 D012189
650    12
$a Rotavirus $7 D012401
650    _2
$a rotavirové infekce $x ekonomika $x terapie $7 D012400
650    _2
$a Slovenská republika $7 D018154
655    _2
$a časopisecké články $7 D016428
700    1_
$a Müllerová, Juliana $u Kantar Health s.r.o., Prague, Czech Republic.
700    1_
$a Jackowska, Teresa $u Department of Pediatrics, the Center of Postgraduate Medical Education, Warsaw, Poland.
700    1_
$a Nemes, Eva $u Department of Pediatrics, Clinical Center, University of Debrecen, Debrecen, Hungary.
700    1_
$a Pazdiora, Petr $u Department of Epidemiology of Medical Faculty, Charles University, Pilsen, Czech Republic.
700    1_
$a Sloesen, Brigitte $u GSK Vaccines, Wavre, Belgium.
700    1_
$a Štefkovičová, Mária $u Faculty of Health Care, Alexander Dubček University of Trenčín, Trenčín, Slovakia.
773    0_
$w MED00196873 $t Value in health regional issues $x 2212-1102 $g Roč. 10, č. - (2016), s. 53-60
856    41
$u https://pubmed.ncbi.nlm.nih.gov/27881278 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20181008 $b ABA008
991    __
$a 20181203090818 $b ABA008
999    __
$a ok $b bmc $g 1341026 $s 1031048
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2016 $b 10 $c - $d 53-60 $e 20160910 $i 2212-1102 $m Value in health regional issues $n Value Health Reg Issues $x MED00196873
LZP    __
$a Pubmed-20181008

Find record

Citation metrics

Logged in users only

Archiving options